

## ABOUT TIGENIX

Advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions.

Lead product, Cx601, filed for EMA registration for the treatment of a severe, debilitating complication of Crohn's disease. Partnered ex-US with Takeda Pharmaceuticals.

Strong pipeline in inflammatory, autoimmune and cardiac diseases.

## QUICK FACTS

**Website:** www.tigenix.com  
**Ticker symbol:** TIG (Euronext & NASDAQ)  
**Headquarters:** Leuven, Belgium  
**Number of employees:** > 100

## UPCOMING MILESTONES

- Start patient enrollment in global phase III trial
- EMA decision on Cx601 EU approval (H2 2017)

## MANAGEMENT

- CEO: **Eduardo Bravo**
- CFO: **Dr. Claudia D'Augusta**
- CTO: **Dr. Wilfried Dalemans**
- CMO: **Dr. Marie Paule Richard**
- VP Regulatory Affairs and Corporate Quality: **Dr. Maria Pascual**
- VP Medical Affairs and Commercialization: **Dr. Mary Carmen Diez**
- Director of Human Resources: **Susana Rojo**

## TECHNOLOGY AND PIPELINE

Two proprietary platforms of expanded allogeneic stem cells:

- Expanded adipose-derived stem cells (eASCs)
- Cardiac stem cells (CSCs)

**Product candidates:**

- **Cx601: locally administered** eASCs for the treatment of **complex perianal fistulas in Crohn's disease patients**. Filed for EMA registration in Q1 2016; Global pivotal phase III trial targeting BLA filing in the US started in H1 2017; **Partnered ex-US with Takeda Pharmaceuticals**.
- **Cx611: Systemic** (IV) administration of eASCs for the treatment of **autoimmune diseases**. Cx611 is currently being evaluated in a **Phase I/II trial in severe sepsis** (the SEPCELL study).
- **AlloCSC-01: Intracoronary administration** of CSCs for the treatment of acute ischemic heart disease. 1 year data from **CAREMI Phase I/II study** demonstrated **safety in acute myocardial infarction** (AMI) and reduction in infarct size in a subset of patients with a large MI and poor prognosis.

## PIPELINE

